Predicting Factors of Long-term Outcome of Gastrointestinal Behçet's Disease: A Chinese Retrospective Study
Xiaoman Zu,Shanshan Xiong,Yaming Lu,Ning Zhang,Shu Xu,Rui Feng,Baili Chen,Zhirong Zeng,Minhu Chen,Yao He
DOI: https://doi.org/10.1016/j.clinthera.2023.12.012
IF: 3.637
2024-01-31
Clinical Therapeutics
Abstract:Purpose Behçet's disease (BD) is a complex disorder affecting multiple systems and organs, and gastrointestinal BD is poorly understood. We aimed to identify factors influencing the long-term outcomes of patients with gastrointestinal BD. Methods Consecutive patients with gastrointestinal BD were analyzed retrospectively. Data on the following clinical characteristics were collected: sex, age at diagnosis, symptoms, endoscopic findings, medical treatments, and surgery. Mucosal healing and surgical rates at 1, 2, and 5 years were evaluated. Log-rank test and Cox proportional hazards regression models were used to evaluate the factors affecting long-term outcomes. Findings Baseline data of 175 patients with gastrointestinal BD were included. The mean (SD) age at diagnosis was 38.3 (12.9) years. The typical clinical symptoms were oral ulcer (72.6%), abdominal pain (71.4%), and weight loss (41.1%). The most commonly involved location was the ileocecum; isolated oval ulcer was the most common ulcer type. Seventeen patients (9.7%) underwent 18 surgeries after inclusion. The cumulative surgical rates were 8.6% (n/N = 15/175), 8.6% (n/N = 15/175), and 9.1% (n/N = 16/175) in 1, 2, and 5 years, respectively. Data from 101 patients who underwent at least 2 endoscopi e s were included in the analysis for mucosal healing. Kaplan-Meier curve showed that the cumulative mucosal healing rates at 1, 2, and 5 years were 34.7% (n/N = 35/101), 41.6% (n/N = 42/101), and 61.4% (n/N = 62/101), respectively. We compared cumulative mucosal healing rates between 4 treatment groups, including 5-aminosalicylic acid (3% [n/N = 3/101]), mono-immunosuppressant (31.7% [n/N = 32/101]), combined therapy (36.6% [n/N = 37/101]), and escalation therapy (28.7% [n/N = 29/101]), and found that mono-immunosuppressant achieved earlier mucosal healing than combined therapy ( P = 0.0008) and escalation therapy ( P = 0.0008). The univariate analysis showed that moderate to severe disease activity ( P = 0.013, P = 0.004), diameter of the maximal ulcer >4 cm ( P = 0.002), and nonsimple esophageal involvement ( P < 0.001) were risk factors, and number of ulcers between 2 and 5 was the protective factor of mucosal healing ( P = 0.001). Multivariate regression analysis indicated that nonsimple esophageal involvement ( P 4 cm ( P = 0.041) were independent risk factors of mucosal healing. Implications Most patients with gastrointestinal BD need long-term treatment to achieve mucosal healing. The location and size of ulcers have a significant impact on the mucosal healing of gastrointestinal BD.
pharmacology & pharmacy